Oral safusidenib begins trial as maintenance for high-grade glioma
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma,…
Latest news & perspectives
Canada agency backs coverage of new ovarian cancer drug
Canada’s Drug Agency (CDA-AMC) has recommended that Canadian public drug plans cover the cost of the gynecological cancer therapy Elahere (mirvetuximab soravtansine) under…
Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with…
